CBN For Glaucoma
The human endocannabinoid system is made up of two main types of receptors: CB 1 and CB 2
The cannabinoid receptors type 2 (CB2) found in immune system-related peripheral tissues and cells appear to be particularly affected by the cannabinol (CBN). The activation of CB2 receptors may hold the key to treating disorders of the peripheral nervous system, including glaucoma. The fact that CB2 does not cause any central side effects is advantageous.
CBN normalizes IOP levels in the eye, stops changes in ECM protein, and helps protect neurons. As a result, CBN has therapeutic potential for glaucoma treatment.
References:
- Somvanshi, R. K., Zou, S., Kadhim, S., Padania, S., Hsu, E., & Kumar, U. (2022). Cannabinol modulates neuroprotection and intraocular pressure: A potential multi-target therapeutic intervention for glaucoma. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease, 1868(3), 166325. https://doi.org/10.1016/j.bbadis.2021.166325
